Main Banners
  • Home
  • Agenda
  • Speakers
  • Companies
  • Sponsors
  • Yelp Guide
  • Blog/News
  • Session Feedback
  • Browse
  • Exhibit Hall Navigation
emergingopp_icon

Emerging Opportunities in Global Markets

China Summit Segment II: Cross-Border Outlook – Access to Capital and Partnering Strategies for the China Market

113ABC: Level 100

Wendy PanBoard of Directors atBayHelix Mr. Michael ChanSenior Vice President atHong Kong Exchanges and Clearing Limited (HKEX) Rich MathenyPartner atGoodwin Mr. Yuquan WangFounding Partner atHaiyin Capital Jinzi J. WuFounder, Chairman and CEO atAscletis Pharma Inc. Dr. Fangfang ZhuVice President atWI Harper Group
emergingopp_icon

Emerging Opportunities in Global Markets

China Summit Segment III: SPOTLIGHT: Aging China and the Implications for Healthcare

113ABC: Level 100

Monica HeDirector, International Affairs atBiotechnology Innovation Organization Wenmeng FengResearch Fellow atDevelopment Research Center of the State Council of the People's Republic of China (DRC) Yan HouVice Chairperson atChina Association of Medical Equipment Melissa Gong MitchellExecutive Director atGlobal Coalition on Aging Paul NeureiterExecutive Director for International Government Affairs atAmgen Inc. Lie-Jun WangDeputy Director General, Division of Social Development Research atDRC Dr. Ding XuVice President, Head of Communications and Government Affairs, Emerging Markets atGSK
emergingopp_icon

Emerging Opportunities in Global Markets

China Summit Segment I: Opening Remarks / Key Regulatory and Policy Trends in Biopharmaceutical Innovation

113ABC: Level 100

Joshua BerlinExecutive Director atBioCentury JianQing ChangVice President, Drug Regulatory Policy atTigermed Jeannette ChuManaging Director atPricewaterhouseCooper Joseph DamondExecutive Vice President, International Affairs atBiotechnology Innovation Organization Christian DavisInternational Trade Partner atAkin Group Ye LiVice President of Government Affairs and Policy atMerck Biopharma China Li YanChief Medical Officer atBrii Biosciences
emergingopp_icon

Emerging Opportunities in Global Markets

China Summit 中国高峰会

113ABC, Level 100

Ye LiVice President of Government Affairs and Policy atMerck Biopharma China
bio2018-mybio-sessionicon-companypres

ChromaTan Corp. Start-Up Stadium

Hall E, Booth 3971, Level 200

Mr. Oleg ShinkazhCEO atChromaTan Corp.
bio2018-mybio-sessionicon-fireside

Fireside Chat with Dr. Norman Sharpless, Acting Commissioner, US Food and Drug Administration

109AB, Level 100

Cartier EshamExecutive Vice President, Emerging Companies atBiotechnology Innovation Organization (BIO) Norman SharplessActing Commissioner atUS Food & Drug Administration
business_icon

Business Development and Finance

Get Relevant or Go Home: Shedding Light on Oncology R&D Sums

107AB, Level 100

Ms. Lisa UrquhartEditor, Vantage atEvaluate Ltd Curtis HechtChief Business Officer atCalithera Biosciences Dr. Paul JuniewiczSr. Director, Oncology Search & Evaluation atTakeda Debi WatsonVice President, Business Development and Licensing atJohnson & Johnson Innovation, Janssen Business Development
bio2018-mybio-sessionicon-companypres

Humabiologics Start-Up Stadium

Hall E, Booth 3971, Level 200

Mr. Dan MahaffeyChief Compliance Officer atHumabiologics
emergingopp_icon

Emerging Opportunities in Global Markets

India's Contribution in Global Biotech R&D

115B, Level 100

Prof. Stephen SammutSenior Fellow Health Care Management. Lecturer - Entrepreneurship atWharton School of Business Kate BealeAssociate Vice President for International Advocacy atPharmaceutical Research and Manufacturers of America, PhRMA Dr. Christiane HamacherCEO atBiocon Biologics India Limited Mr. Amit KapoorHonorary Chairman atInstitute for Competitiveness, India Dr. Cyrus KarkariaPresident atLupin Limited Dr. Alka SharmaScientist G atDepartment of Biotechnology, Government of India
business_icon

Business Development and Finance

Leveraging America’s Seed Fund (SBIR/STTR) to Accelerate Life Sciences Technology Development and Secure Follow-On Investments

109AB, Level 100

Ashim SubedeeProgram Director atNCI Small Business Innovation Research (SBIR) Development Center Dr. Matthew PortnoyProgram Manager, NIH SBIR/STTR Program atNational Institutes of Health Michal PremingerHead, J&J Innovation, East North America atJohnson & Johnson Innovation Allen ReitzCEO atFox Chase Chemical Diversity Center, Inc. Stephanie StehmanPrincipal atOsage University Partners
translationalresearch

Translational Research

New Models for Translational Research Collaboration

112AB, Level 100

Mary WoolleyPresident atResearch America Christopher AustinDirector, National Center for Advancing Translational Sciences (NCATS) atNational Institutes of Health Aoife BrennanPresident & CEO, CMO atSynlogic Mikael DolstenChief Scientific Officer and President, Worldwide Research, Development and Medical atPfizer, Inc. Jon EpsteinExecutive Vice Dean and Chief Scientific Officer William Wikoff Smith Professor of Cardiovascular Research Department of Medicine atPerelman School of Medicine University of Pennsylvania Lynn O'Connor VosCEO atMuscular Dystrophy Association
intellectualproperty_icon

Intellectual Property

The BPCIA is Turning Ten: What's Next for Biosimilars?

118C, Level 100

Steven MaslowskiPartner atAkin Gump Strauss Hauer & Feld LLP Paul GolianVice President & Assistant General Counsel atBristol-Myers Squibb Julia PikeVice President of Intellectual Property, North America atSandoz Chandrika ViraDirector atSterne, Kessler, Goldstein & Fox P.L.L.C.
emergingopp_icon

Emerging Opportunities in Global Markets

There is $200B in Global Investment in the Biopharmaceutical Sector Each Year. Who’s Getting It and Why?

115A, Level 100

Meir Pugatch Managing Director & Professor atPugatch Consilium; University of Maastricht Dr. Woei-Jer ChuangDirector General, Department of Life Sciences atMinistry of Science and Technology, Taiwan Ancizar Guerrero GilForeign Investment Executive Director in the United States atProcolombia Park Jee MinDeputy Director of the Division of Health Industry Promotion atMinistry of Health and Welfare (MoHW) Michael PergineAssociate Vice President, International Policy and Government Affairs atMerck & Co. Prof. Peter PittsPresident and Co-Founder atCenter for Medicine in the Public Interest
bio2018super_sessions

What’s Next: The Landscape of Innovation in 2019 and Beyond

103ABC, Level 100

Barbara DaltonVice President, Worldwide Business Development atPfizer Inc. Dr. David DonabedianCo-founder, CEO and Director atAxial Biotherapeutics Chris GarabedianChairman and CEO atXontogeny, LLC Curt HerbertsChief Financial Officer and Chief Business Officer atSenti Biosciences, Inc. David ThomasVice President, Industry Research atBiotechnology Innovation Organization Ben ThornerSenior Vice President & Head, MRL Business Development & Licensing atMerck & Co., Inc. Sam UlinManaging Director atClearView Healthcare Partners
oncologyicon

Oncology

What Was Hot at ASCO 2019? Highlights from the World’s Biggest Oncology Meeting

105AB, Level 100

Ted TentoffSr. Research Analyst atPiper Jaffray Sam AgrestaChief Medical Officer atInfinity Pharmaceuticals Roy BaynesSenior Vice President, Global Clinical Development & Chief Medical Officer atMerck Research Laboratories Howard "Skip" BurrisPresident atASCO Patricia KeeganDirector, Division of Oncology Products 2 atCenter for Drug Evaluation and Research (CDER), FDA Dr. Thomas LynchExecutive Vice President, Chief Scientific Officer atBristol-Myers Squibb
Powered by Eventsforce Copyright 2021. Privacy Support